Santiago Muñoz Fernández-rekin lankidetzan egindako argitalpenak (6)

2024

  1. Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies

    Revista Chilena de Infectologia, Vol. 40, Núm. 6, pp. 618-625

  3. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors

    Vaccines, Vol. 11, Núm. 10

2022

  1. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 28, Núm. 2, pp. e348-e352

  2. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

    JCR: Journal of Clinical Rheumatology, Vol. 28, Núm. 2, pp. e348-e352